Clozapine consistently ranks as the most efficacious antipsychotic medication in large-scale analyses comparing dozens of available drugs. A 2019 network meta-analysis of 32 oral antipsychotics placed clozapine at the top for reducing overall symptoms of schizophrenia, followed by amisulpride, zotepine, olanzapine, and risperidone. But “strongest” is a slippery word in psychiatry, because chemical potency, clinical efficacy, and real-world effectiveness are three different things, and the drug that wins on one measure doesn’t necessarily win on the others.
What the Largest Comparisons Actually Found
The most comprehensive head-to-head ranking of antipsychotics comes from a systematic review and network meta-analysis published in The Lancet, which pooled data from over 400 trials involving more than 50,000 participants with multi-episode schizophrenia. Clozapine produced the largest reduction in overall symptoms compared with placebo, and it separated itself from most other drugs in direct comparisons. Amisulpride, olanzapine, and risperidone also outperformed many competitors, but most of the remaining drugs were statistically hard to tell apart.1The Lancet. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis – Section: Results
A more recent analysis tried to bridge the gap between clinical trials and the real world by combining randomized controlled trial data with national registry data. When real-world evidence was analyzed on its own, clozapine again came out on top, followed by long-acting injectable olanzapine. When both types of evidence were merged, olanzapine ranked as the most efficacious among drugs that appeared in both datasets.2PubMed. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data The fact that rankings shift depending on the type of evidence examined tells you something important: no single drug is objectively and universally “the strongest.” Context matters enormously.
Potency and Efficacy Are Not the Same Thing
When people ask about the “strongest” antipsychotic, they often conflate two concepts. Potency refers to how little of a drug you need to produce a given pharmacological effect, while efficacy refers to how much symptom improvement a drug can produce at its best dose. These don’t track together.
Haloperidol, for instance, is a high-potency antipsychotic. You need only a few milligrams per day to achieve the same dopamine receptor blockade that would require hundreds of milligrams of chlorpromazine. Researchers have developed formal dose-equivalence tables mapping how much of each antipsychotic corresponds to a standard reference dose of chlorpromazine or haloperidol.3PubMed Central. Dose Equivalents for Antipsychotic Drugs: The DDD Method But haloperidol’s high potency does not make it more effective at clearing psychotic symptoms than lower-potency drugs. Clozapine, which requires doses in the range of 300 to 900 milligrams daily, outperforms haloperidol in treatment-resistant patients despite needing a far larger pill.
All currently used antipsychotics share the property of blocking dopamine receptors, particularly the D2 subtype. Where they differ is in what else they do: which other receptors they bind, how tightly they hold on, and what side-effect profile results.4Acta Psychiatrica Scandinavica. Clinically relevant differences between antipsychotic compounds One study comparing the receptor binding profiles of 35 antipsychotics found that the number of different receptors a drug interacts with has no relationship to how well it works clinically.5PubMed. Comparative receptor pharmacology of antipsychotic drugs based on normalized binding affinity data and breadth of interaction A drug can bind to a dozen receptor types and still be mediocre at treating psychosis.
The Dopamine Occupancy Sweet Spot
Brain imaging studies have identified a window of dopamine D2 receptor occupancy that predicts both response and side effects. Clinical response becomes likely once a drug occupies about 65% of D2 receptors. But once occupancy climbs above roughly 78 to 80%, the risk of movement-related side effects and elevated prolactin levels rises sharply.6PubMed. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia7PubMed Central. Antipsychotic occupancy of dopamine receptors in schizophrenia The ideal range sits between roughly 65% and 80%, and dose recommendations for newer drugs have been shaped by this imaging evidence.
Clozapine is unusual here. Despite its top-ranking efficacy, it actually occupies far fewer D2 receptors than most competitors. In one imaging study, clozapine-treated patients showed only about 5% D2 occupancy in the midbrain, compared with about 28% for olanzapine and 40% for haloperidol.8PubMed. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine This suggests that clozapine’s superiority doesn’t come from stronger dopamine blockade. It comes from something else entirely, likely its broad activity across serotonin, histamine, muscarinic, and adrenergic receptors. The receptor profile of olanzapine is quite similar to that of clozapine, which may partly explain why olanzapine often ranks close behind it.9Neuropsychopharmacology. Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Why Clozapine Is Saved for Treatment-Resistant Cases
If clozapine is the most efficacious antipsychotic, you might wonder why it isn’t the first drug prescribed. The short answer is side effects. Clozapine carries a risk of a potentially fatal drop in white blood cells called agranulocytosis, which requires regular blood monitoring. It also causes substantial weight gain, metabolic disturbances including elevated blood sugar and lipid levels, and heavy sedation. These metabolic side effects aren’t unique to clozapine; olanzapine, quetiapine, and risperidone are also associated with significant weight gain and diabetes risk. But clozapine’s blood-monitoring requirement and its overall burden of side effects push it to the back of the line in most treatment guidelines.10PubMed Central. A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
The landmark study that established clozapine’s role was a double-blind trial in people whose schizophrenia had not responded to other antipsychotics. About 30% of clozapine-treated patients met criteria for meaningful improvement, compared with just 4% on chlorpromazine. The improvement extended to both positive symptoms like hallucinations and negative symptoms like social withdrawal.11JAMA Psychiatry. Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine A later network meta-analysis focused specifically on treatment-resistant schizophrenia confirmed that clozapine, risperidone, and olanzapine all outperformed haloperidol, with clozapine and risperidone showing the clearest advantages.12JAMA Psychiatry. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis – Section: Results
In practice, treatment guidelines reserve clozapine for patients who haven’t responded adequately to at least two other antipsychotics tried at adequate doses. That means the vast majority of people treated for psychosis will never take clozapine, and for most of them, the differences among the other top-ranked drugs are modest enough that the choice often comes down to side-effect profile rather than efficacy.
Different Symptoms Respond to Different Drugs
Schizophrenia isn’t a single symptom. Positive symptoms (hallucinations, delusions, disorganized thinking) are the most dramatic, but negative symptoms (blunted emotion, social withdrawal, lack of motivation) and cognitive difficulties often cause more long-term disability. Antipsychotics don’t treat all three domains equally well.
A dose-response meta-analysis found that the doses needed to reach peak effectiveness for negative symptoms were often different from those needed for positive symptoms. Olanzapine, for example, needed a higher daily dose for negative symptoms than for positive ones, while the pattern reversed for some other drugs like asenapine.13npj Schizophrenia. Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials – Section: Results This means that the “strongest” drug for one symptom cluster may not be the strongest for another.
Newer partial dopamine agonists like aripiprazole, brexpiprazole, and cariprazine work differently from traditional antipsychotics. Rather than simply blocking dopamine receptors, they partially activate them, which can stabilize dopamine signaling without shutting it down entirely. Their acute antipsychotic effects are broadly comparable to each other, but cariprazine has shown a particular advantage for primary negative symptoms.14PubMed Central. Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? For cognition, most second-generation antipsychotics appear to have modestly positive effects, though the evidence is mixed and the improvements are generally small.15PubMed Central. The Effect of Antipsychotics on Cognition in Schizophrenia—A Current Narrative Review – Section: Results
First Episode Changes the Equation
How well antipsychotics work depends heavily on where someone is in the course of illness. A comparison of meta-analyses found that people experiencing their first psychotic episode were far more likely to respond to treatment than those with multiple previous episodes. Roughly four out of five first-episode patients showed at least a minimal response, compared with about half of multi-episode patients. A strong response, defined as a 50% or greater reduction in symptom scores, occurred in about half of first-episode patients but only about a quarter of those with established illness.16PubMed Central. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses
This means that the question of which drug is “strongest” is partly a question about the patient. In a first episode, most antipsychotics work reasonably well, and the decision is driven more by tolerability and individual preferences. The deeper into illness someone is, the more the efficacy differences between drugs begin to matter, and the more the case for clozapine strengthens.
Why the Same Drug Works Differently in Different People
Genetic variation plays a real role in how someone responds to antipsychotics. A meta-analysis found that variations in the gene encoding the D2 dopamine receptor are associated with differences in clinical response to antipsychotic treatment.17PubMed Central. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis Variations in serotonin receptor genes may also influence efficacy, and genetic differences in the liver enzymes that metabolize these drugs (the cytochrome P450 system) can affect both how well a drug works and how many side effects it causes.18PubMed. Pharmacogenetics of psychotropic drug response
Clozapine is a particularly clear example. It is primarily broken down by the CYP1A2 enzyme, and genetic variants in this enzyme can make some people metabolize clozapine much faster or slower than average. Cigarette smoking further complicates this because it induces CYP1A2 activity, meaning smokers may need higher clozapine doses to reach the same blood levels.19JURNAL PEMBELAJARAN DAN BIOLOGI NUKLEUS. The Influence of Genetic Variations in CYP1A2 Associated with Clozapine Metabolism in Schizophrenia Patients This is one reason why the “strongest” drug on paper may not be the strongest drug for a given individual. Pharmacogenomic testing is becoming more common in psychiatry, though it’s still far from routine.
Long-Acting Injectables and Real-World Effectiveness
One of the biggest predictors of relapse in schizophrenia is simply not taking the medication. Long-acting injectable antipsychotics, given every few weeks or even every few months, remove the daily pill-taking variable from the equation. A network meta-analysis of injectable formulations found that most outperformed placebo for relapse prevention, with paliperidone (three-month formulation) and aripiprazole ranking highest.20PubMed. Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis
The evidence on whether injectables are truly superior to pills in preventing relapse is nuanced. A meta-analysis of 21 randomized trials found no clear overall advantage for injectables over oral antipsychotics, though older first-generation injectable formulations did show a modest benefit.21PubMed Central. Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials Randomized trials can understate the real-world advantage of injectables, though, because people who agree to participate in a clinical trial and accept randomization tend to be relatively adherent to their medications regardless. A mirror-image study following patients before and after they switched to injectables found that relapse rates dropped from about 86% to 66% overall.22PubMed Central. Impact of treatment with long‑acting injectable antipsychotics on hospitalization and relapse rates in schizophrenia spectrum disorders: a 3‑year follow-up mirror‑image study – Section: Results The “strongest” drug, in a practical sense, may sometimes be whichever one actually gets taken consistently.
Why Combining Antipsychotics Usually Backfires
When a single antipsychotic isn’t working well enough, clinicians sometimes add a second one. This practice is common despite guidelines generally warning against it. A large meta-analysis found that antipsychotic polypharmacy was associated with about a 42% higher risk of relapse compared with monotherapy, along with worse overall functioning, more movement-related side effects, and a longer cardiac QT interval.23The Lancet Psychiatry. Global prevalence, trends, and correlates of antipsychotic polypharmacy: a systematic review and meta-analysis Multiple antipsychotics together tend to push total doses higher, increase the risk of drug interactions through the liver’s metabolic pathways, raise medication costs, and make it harder for patients to stick with complicated pill schedules.24International Journal of Neuropsychopharmacology. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia – Section: Potential disadvantages of antipsychotic polypharmacy
There is one exception that gets some support in the evidence: combining clozapine with a partial dopamine agonist like aripiprazole. This particular combination may help reduce some of clozapine’s metabolic side effects or address residual symptoms without compounding the D2 blockade excessively.25PubMed Central. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations Outside of that specific pairing, the evidence strongly favors optimizing a single antipsychotic before resorting to combinations.
A New Drug Class That Skips Dopamine Entirely
Every antipsychotic approved before 2024 works primarily by blocking dopamine D2 receptors. Xanomeline-trospium, approved by the FDA under the brand name Cobenfy, is the first antipsychotic that operates through a completely different mechanism: it activates muscarinic cholinergic receptors instead of blocking dopamine. This is a genuinely novel approach that psychiatry has been waiting decades for.
The clinical evidence is promising. In one randomized trial, xanomeline-trospium reduced symptom scores by about 17 points more than placebo over five weeks.26PubMed Central. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia – Section: RESULTS A subsequent trial showed a roughly 10-point advantage over placebo, with improvement in both positive and negative symptoms.27The Lancet. Efficacy and safety of xanomeline–trospium chloride in schizophrenia, a randomised, double-blind, placebo-controlled, phase 3 trial (EMERGENT-2) A third trial confirmed statistically significant symptom reduction with a moderate effect size.28JAMA Psychiatry. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial – Section: Results
Because it doesn’t block dopamine, xanomeline-trospium avoids many of the side effects people associate with antipsychotics: movement disorders, prolactin elevation, and the heavy sedation that comes from strong D2 blockade. Its main side effects are gastrointestinal, including nausea and constipation, which is why the trospium component (an anticholinergic that doesn’t cross into the brain) was added to counteract peripheral muscarinic activation. Whether this drug class will eventually rival clozapine for treatment-resistant cases is unknown. The trials so far studied patients with schizophrenia broadly, not specifically treatment-resistant populations. But for people who cannot tolerate dopamine-blocking drugs, or for whom those drugs aren’t working well enough, a fundamentally different mechanism of action represents a meaningful new option. It also challenges the long-held assumption that dopamine blockade is a necessary ingredient for antipsychotic efficacy.